<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925324</url>
  </required_header>
  <id_info>
    <org_study_id>STEMVAD-001</org_study_id>
    <nct_id>NCT03925324</nct_id>
  </id_info>
  <brief_title>Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device</brief_title>
  <acronym>STEM-VAD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of the Safety and Efficacy of Intravenous Delivery of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients and Implanted Left Ventricular Assist Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rebecca Torguson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the safety and preliminary efficacy of serial intravenous dose of
      Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left
      ventricular assist devices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, placebo-controlled, single-center, randomized study to assess the safety and
      preliminary efficacy of a three serial intravenous doses of allogeneic mesenchymal bone
      marrow cells to subjects with heart failure and implanted left ventricular assist devices.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temperature</measure>
    <time_frame>up to 12 months post enrollment</time_frame>
    <description>Temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncontrolled systemic infection</measure>
    <time_frame>up to 12 months post enrollment</time_frame>
    <description>Number of admission for uncontrolled systemic infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>up to 12 months post enrollment</time_frame>
    <description>Rate of Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NK cell depletion</measure>
    <time_frame>Baseline to day 90</time_frame>
    <description>percent reduction in NK cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the following cardiac biomarker</measure>
    <time_frame>Baseline and day 90 post initial infusion</time_frame>
    <description>The change in the lab values N-Terminal Prohormone of Brain Natriuretic Peptide (NT-ProBNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RV systolic function</measure>
    <time_frame>Baseline and day 90 post initial infusion</time_frame>
    <description>Change in RV systolic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations due to right heart failure</measure>
    <time_frame>day 90</time_frame>
    <description>Number of hospitalizations for to right heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance changes</measure>
    <time_frame>Baseline and day 90 post initial infusion</time_frame>
    <description>6 minute walk distance changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gout flares</measure>
    <time_frame>Day 90</time_frame>
    <description>Count of gout flares</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)</intervention_name>
    <description>Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg</description>
    <arm_group_label>Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1.5 mL/kg Lactated Ringer's Solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years.

          2. Advanced Heart Failure

          3. Advanced HF defined as HF requiring LVAD implantation and deemed stable on his/her
             LVAD.

          4. On stable medical therapy (per the discretion of the treating physician) including
             beta-blockers, ACE-inhibitors, angiotensin receptors blockers, angiotensin receptor
             neprilysin inhibitor, mineralocorticoid receptor antagonists, isosorbide, hydralazine,
             and mineralocorticoid receptor antagonists) and optimized pump speed for at least a
             month prior to randomization.

          5. HS-CRP level≥2 mg/l.

          6. NYHA class II-III symptoms.

          7. Ability to understand and provide signed informed consent.

          8. Reasonable expectation that patient will receive standard post-treatment care and
             attend all scheduled safety follow-up visits

        Exclusion Criteria:

          1. Women of childbearing potential. Postmenopausal women or women with permanent
             contraception method (defined as total hysterectomy) will not be excluded.

          2. History of debilitating stroke (modified Rankin Score &gt; 3) within 3 months.

          3. The likelihood of requirement of cardiac surgery during the study period.

          4. Presence of clinically significant, uncorrected left sided valvular heart disease,
             active acute myocarditis, or uncontrolled hypertension defined as Persistently
             elevated mean arterial blood pressure (&gt;100 mmHg). Echocardiography within 12 months
             of screening. Patients can be re-evaluated, at the discretion of the investigator.

          5. QTc &gt;550 ms (in the absence of bundle branch block, interventricular conduction delay
             or ventricular pacing). Electrocardiogram (ECG) within 60 days.

          6. History of cardiac arrest within 3 months.

          7. Hypertrophic or infiltrative cardiomyopathy.

          8. Considered or listed for organ transplantation or history of organ transplantation

          9. Illness other than HF with life expectancy less than 12 months.

         10. Enrolled in an interventional trial or received an experimental drug or device within
             30 days of randomization.

         11. Left ventricular assist device implantation &gt;2 years prior to enrollment.

         12. Biventricular assist device (Bi-VAD) support.

         13. Severe COPD defined by FEV1&lt;1L, FEV1/FVC&lt;70% within 12 months if known history of
             COPD, otherwise FEV1&lt;1L, FEV1/FVC&lt;70% within 24 months

         14. Uncontrolled seizure disorder.

         15. Clinically significant hematologic, hepatic, or renal impairment as determined by
             screening clinical laboratory tests within the last 30 days:

             Liver disease = ALT or AST &gt; 3x normal, alkaline phosphatase or bilirubin &gt;2x normal
             Renal disease = on long term dialysis Hematologic = Unexplained persistent
             leukocytosis (WBC &gt;11 K/UL) or hemoglobin &lt; 8.5 gm/dl

         16. Presence of any other clinically-significant medical condition, psychiatric condition,
             or laboratory abnormality, that in the judgment of the investigator or sponsor may
             affect compliance with the study protocol or pose a safety risk to the subject.

         17. Inability to comply with the conditions of the protocol.

         18. Acute coronary syndrome within 4 weeks (clinical diagnosis, confirmed by
             electrocardiographic abnormalities and elevation of troponin-I).

         19. Malignancy within the previous five years, except adequately treated basal cell
             carcinoma, provided that it is neither infiltrating nor sclerosing, and carcinoma in
             situ of the cervix.

         20. Active uncontrolled systemic infection. Positive blood or deep tissue cultures or
             clinical or imaging evidence of systemic infection despite complete course of
             effective antimicrobial therapy as determined by infectious diseases. Localized
             (non-systemic) infection is not an exclusion criterion. Patients can be re-evaluated,
             at the discretion of the investigator.

         21. Early postpartum cardiomyopathy (within six months of diagnosis).

         22. Presence of inherited or acquired immune deficiency or human immunodeficiency virus
             infection (HIV). Negative HIV test within the preceding 12 months is required.

         23. Systemic corticosteroids, immunosuppressive drug therapy (cyclophosphamide,
             methotrexate, cyclosporine, tacrolimus, azathioprine, mycophenolate, sirolimus, etc.),
             and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment.

         24. Known Porphyria.

         25. Allergy to sodium citrate or any caine type of local anesthetic.

         26. Patient enrolled in hospice care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebecca Torguson</last_name>
    <phone>202-877-5979</phone>
    <email>rebecca.torguson@medstar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selma Mohammed, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>December 27, 2019</last_update_submitted>
  <last_update_submitted_qc>December 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medstar Health Research Institute</investigator_affiliation>
    <investigator_full_name>Rebecca Torguson</investigator_full_name>
    <investigator_title>Director, Clinical Research Operations</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

